Home › Funds › Bellevue Group AG › BBIO

Bellevue Group AG position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Bellevue Group AG reported holding 1,189,506 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q2 2026 13F filing — a position valued at US$88.6M, representing 1.86% of its reported portfolio and ranking #17 among its reported holdings. Bellevue Group AG has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.19M sh
Reported value held$88.59M
Portfolio Weight1.86%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bellevue Group AG's BBIO position evolved

Bellevue Group AG first disclosed a stake in BBIO in Q3 2023 at 78,700 shares (US$2.1M). The position peaked in Q2 2026 at 1,189,506 shares, worth US$88.6M. Across 12 filings, Bellevue Group AG increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 1,189,506 shares valued at US$88.6M — an increase of 1,164,129 shares quarter over quarter.. Notable position changes include a 62% trim in Q1 2024 (shares fell 18% over the following quarter), a 96% increase in Q3 2025 (shares rose 47% over the following quarter), a 4587% increase in Q2 2026 (shares fell 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 78.70K $2.08M New
Q4 2023 33.30K $1.34M Reduce
Q1 2024 12.80K $395.78K Reduce
Q2 2024 12.80K $324.22K Hold
Q3 2024 10.40K $264.78K Reduce
Q4 2024 10.40K $285.38K Hold
Q1 2025 10.40K $359.53K Hold
Q2 2025 10.40K $449.07K Hold
Q3 2025 20.36K $1.06M Add
Q4 2025 24.11K $1.84M Add
Q1 2026 25.38K $1.88M Add
Q2 2026 1.19M $88.59M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 47 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Bellevue Group AG held BBIO?

Bellevue Group AG has disclosed BBIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Bellevue Group AG's current position in BBIO?

As of Q2 2026, Bellevue Group AG holds 1.19M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $88.59M, representing 1.86% of its reported portfolio and ranking #17.

Has Bellevue Group AG been buying or selling BBIO?

In the latest 13F filing (Q2 2026), Bellevue Group AG increased its position in BBIO. The position peaked in Q2 2026 at 1.19M shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.